Skin autofluorescence and glycemic variability

Diabetes Technology and Therapeutics

Volumn 12, Issue 7, 2010, Pages 581-585

  Noordzij, M J ^a   Lefrandt, J D ^a   Graaff, R ^a   Smit, A J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

ADULT; AUTOFLUORESCENCE IMAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCEMIC INDEX; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE MEASUREMENT; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; FLUORESCENCE; METABOLISM; MIDDLE AGED; SKIN;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; FLUORESCENCE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; SKIN;

EID: 77954451184     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2010.0014     Document Type: Review

References (18)

1. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995;46:223-234.
2. Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ, Gans RO, Bilo HJ: Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 2008;31:517-521.
3. Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO, Smit AJ: Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007; 30:107-112.
4. Lutgers HL, Gerrits EG, Graaff R, Links TP, Sluiter WJ, Gans RO, Bilo HJ, Smit AJ: Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 2009; 52:789-797.
5. Hartog JW, de Vries AP, Lutgers HL, Meerwaldt R, Huisman RM, Van Son WJ, de Jong PE, Smit AJ: Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci 2005;1043: 299-307.
6. Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans RO, Smit AJ: Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3687-3693.
7. Basta G: Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008;196:9-21.
8. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO, Smit AJ: Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:1324-1330.
9. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
10. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-3167
11. Goldberg T, CaiW, Peppa M, Dardaine V, Baliga BS, Uribarri J, Vlassara H: Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004;104:1287-1291. Erratum in: J Am Diet Assoc 2005;105:647.
12. Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H: Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005;1043:461-466.
13. Stirban A, Nandrean S, Negrean M, Koschinsky T, Tschoepe D: Skin autofluorescence increases postprandially in human subjects. Diabetes Technol Ther 2008;10:200-205.
14. Gerrits EG, Lutgers HL, Kleefstra N, Groenier KH, Smit A, Gans ROB, Bilo HJG: Skin advanced glycation end product accumulation is poorly reflected by glycemic control in type 2 diabetic patients (ZODIAC 9). J Diabetes Sci Technol 2008;2:572-577.
15. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachin J, Genuth S: Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999;48:870-880.
16. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM; DCCT Skin Collagen Ancillary Study Group: Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications participants with type 1 diabetes. Diabetes 2005;54:3103-3111.
17. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, Smit AJ: Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006;29:2654-2659.
18. Maynard JD, Rohrscheib M, Way JF, Nguyen CM, Ediger MN: Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C. Diabetes Care 2007;30:1120-1124.